key: cord-0868571-bpzwx27u
authors: Massoomi, Michael R.; Anderson, R. David; Ahmed, Mustafa M.; Dasa, Osama; George, Philip; Miles, William M.; Aranda, Juan M.; Pepine, Carl J.
title: Cardiovascular Considerations for the Internist and Hospitalist in the COVID-19 Era
date: 2020-07-10
journal: Am J Med
DOI: 10.1016/j.amjmed.2020.06.005
sha: be040de2385e16c635984fb0c4b5be9be8707301
doc_id: 868571
cord_uid: bpzwx27u

It is clear that existing cardiovascular disease is a major risk factor for COVID-19 and related adverse outcomes. In addition to acute respiratory syndrome, a large cohort also develop myocardial and/or vascular dysfunction, in part from inflammation and renin angiotensin system activation with increased sympathetic outflow, cardiac arrhythmias, ischemia, heart failure, and thromboembolic complications that portend poor COVID-19 outcomes. We summarize here recent information for hospitalists/internists on the front-line of this pandemic regarding its cardiovascular impacts and management and need for cardiovascular consultation.

The COVID-19 pandemic focuses on respiratory manifestations, but evidence has emerged relative to major cardiovascular implications. Preexisting cardiovascular conditions increase risk for COVID-19 and also for cardiovascular manifestations sometimes leading to death. Understanding this aspect is imperative for the internal medicine community. Cardiovascular manifestations range from arrhythmias to acute cardiomyopathies, myocarditis, thromboembolic disorders, to shock. Conversely in presentations appearing to be cardiovascular, COVID-19 infection should also be considered. 1 Given the extent and variability of cardiovascular manifestations, care of these patients is challenging and includes direct virus effects and possible iatrogenic effects from treatments.

Cardiologists should be prepared to assist other specialties in managing these cardiac complications and protocols for triaging, diagnosing, and managing COVID-19 patients with cardiovascular complications should be refined as data become available.

Caution should be exercised since classical myocardial infarction symptoms may be obscured leading to underdiagnosis of cardiac injury or overdiagnosis and inappropriate diagnostic testing/imaging during shortages in protective equipment and staffing.

This review provides recommendations for a systematic approach to the cardiovascular evaluation of patients with COVID-19 for the internist/hospitalist.

Pressing COVID-19 related cardiovascular queries faced by front-line physicians, from baseline cardiac evaluation needed, to appropriate cardiac imaging, and timing of cardiology input are addressed. 5 

Clinical data (symptoms, electrocardiography [ECG] , and echocardiography) and cardiac troponin (cTn) are key to evaluate myocardial injury in COVID-19. High sensitivity (hs) cTn increases our ability to detect cardiomyocyte injury resulting from a variety of processes (ischemia, hypoxia, microvascular dysfunction, microvascular thrombosis, cytokine storm, myocarditis, underlying heart failure, etc.). Among COVID-19 patients with cTn >99th percentile mortality may approach ~50% versus ~5% without cTn elevation. 2,3. Rapidly obtainable, cTn is very useful for identifying increased mortality risk. Interpretation using the 4 th -universal definition of myocardial infarction 4 maintains standardized language regarding cTn patterns and facilitates appropriate cardiovascular consultation, since >20% of hospitalized COVID-19 patients may have elevated cTn. 2, 3, 5 An initial negative cTn does not necessarily require repeat testing unless indicated clinically, to exclude acute coronary syndrome ( Figure-1 ). An initial elevated cTn should be trended to clarify the injury pattern as acute vs chronic/stable and to quantify the injury. Testing frequency should be based clinical and laboratory findings to minimize extra testing and staff exposure.

Among COVID-19 patients with elevated cTn, we recommend echocardiography as a baseline and to identify pre-clinical left-ventricular dysfunction that may portend poor prognosis. Patients with low levels of cTn (chronic injury pattern), without clinical heart failure or echocardiographic abnormalities, may be managed conservatively with close monitoring. Acute myocardial injury may be further delineated with brain natriuretic peptide, clinical findings, repeat ECGs and echocardiography to guide care.

These patients have a broad differential diagnosis since multiple factors may affect cTn, 6 (e.g. renal disease, coronary artery disease, etc.) so, setting a threshold level to trigger consultation is challenging. Concern for acute coronary syndrome or heart failure signal important opportunities for consultation.

Anticoagulation COVID-19 patients are at elevated risk for venous thromboembolism and/or microvascular thrombosis. Prophylactic anticoagulation with low-molecular-weight heparin is recommended for patients without contraindications. 6, 7 Some attempt to riskstratify by trending d-dimer levels. We suggest maintaining anticoagulation in patients with another indication for anticoagulation (e.g. atrial fibrillation, mechanical valve, known venous thromboembolism, etc.). Of note, apixaban and rivaroxaban levels may be increased in patients treated with sarilumab or tocilizumab and alternative agents should be considered in this setting. Warfarin may need to be increased with closer monitoring. When to initiate anticoagulation in patients without thromboembolic events is unknown but may be considered in patients with significantly elevated d-dimer levels as part of a clinical trial.

Approach to Acute Myocardial Injury in the COVID-19 Era

Internists are skilled at initial assessment and therapeutic decision making for suspected acute coronary syndromes. Multiple and varied myocardial effects of COVID-19 are apparent, and patients with preexisting cardiovascular disease are at increased risk for adverse outcomes. 2 COVID-19 complications may render decision making more difficult in patients with presumed acute coronary syndrome. Patients presenting with 7 myocardial injury in the setting of COVID-19 may have a Type-1 myocardial infarction with atherothrombosis and coronary occlusion due to acute plaque rupture/erosion. These patients may also present with viral myocarditis, stress-related cardiomyopathy, another form of non-ischemic cardiomyopathy, coronary vasospasm, or non-specific injury without Type-1 or 2 myocardial infarction. 8 Among NYC patients, 3-7% had a cardiac complication. 9 In 18 patients with ST-elevation, more than half had it at emergency department presentation and the remainder developed ST elevation later.

Only one third of ST elevation patients had chest pain and the majority were men. The pattern of ST elevation was diffuse in 22%. Of nine patients who underwent coronary angiography, six had disease and only five underwent percutaneous coronary intervention. 10 Importantly, 72% of these patients died. While this is a small series, it illustrates the varied presentations for COVID-19 patients and management challenges.

COVID-19 has prompted re-evaluation of established algorithms for care for STsegment elevation myocardial infarction (STEMI) and many non-STEMI (NSTEMI) patients. A balance is needed between invasive therapy in acute coronary syndrome patients in the pandemic environment and contamination protection of healthcare workers and facilities. The number of STEMI activations has declined 11 , suggesting that patients in need of acute care are not seeking it due to fear of presenting to hospital.

Another concern is the possibility of misdiagnosis or "missed" diagnosis when the focus is solely on the respiratory issues.

The following are strategies will hopefully assist the internist/hospitalist manage COVID-19 patients presenting with evidence for acute myocardial injury (Figure-2). 8 

The approach to chest pain patients with STEMI should not differ from before this pandemic. Evaluation should include clinical assessment and an ECG. Primary PCI is recommended within 90 minutes of presentation and centers without access to primary PCI within 90 minutes should consider thrombolytic therapy. In the current era, STEMI patients should be considered COVID-19 positive. 12 If SARS-CoV-2 testing is rapidenough to impact decision making it may be used to streamline care. Cardiology consultation may be helpful in distinguishing Type-1 STEMI from virus-associated Type-2 STEMI mimics such as myopericarditis. Delays in reperfusion may occur if studies such as echocardiography or computed tomography are required when ECGs or symptoms are atypical. The goal remains timely primary PCI whenever possible. While thrombolytic therapy may be considered at centers without PCI capabilities, patients with ST elevation from one of the Type-2 causes of myocardial infarction seen with COVID-19 may be exposed to bleeding risks without benefit. Currently, COVID-19 patients requiring intubation have a very high mortality so those who develop a STEMI may be considered for palliative care after discussions with family or caregivers. 13 Unstable Angina or NSTEMI Myocardial Injury Without ST elevation biomarker elevation in COVID-19 patients is difficult to interpret. They may have Type-1 myocardial infarction with atherothrombosis or other causes of myocardial injury may be present as above. The challenge is deciding when to utilize the catheterization laboratory. Stable patients can be managed conservatively until SARS-CoV2 status is known. Before COVID-19, NSTEMI or unstable angina 9 patients were often treated conservatively before invasive procedures. Exceptions include hemodynamic or electrical instability, a high Global Registry of Acute Coronary Events (GRACE) score, or other high-risk feature. These patients should be offered an invasive evaluation and intervention if indicated. Patients without high-risk features can be managed conservatively until they either test negative for SARS-CoV2 or, until the infection has resolved. All patients should receive guideline-directed medical therapy. 12. Cardiogenic Shock or Out-of-Hospital Cardiac Arrest Patients with cardiogenic shock or out-of-hospital cardiac arrest remain very high risk for death. Before COVID-19 there was lack of consensus about taking these patients to cardiac catheterization. In the current environment it is recommended that resuscitated out-of-hospital cardiac arrest patients be considered for invasive therapy when presenting with STEMI. Those who are hemodynamically unstable or in cardiogenic shock, may also be considered for invasive cardiac evaluation despite their ECG findings. Mechanical circulatory support may be considered after consultation with an advanced heart failure team.

An unexpected challenge of COVID-19 is management of heart failure beginning pre-hospital since undifferentiated symptoms may be mischaracterized, causing delay/ confusion in management, and potential inappropriate treatment. Furthermore, if these patients require in-person assessment, symptom-based virtual assessment is needed to preserve healthcare and personal protective resources, while limiting exposure of 10 vulnerable patients. Virtual assessment should focus on features that increase the probability of COVID-19 versus only heart failure exacerbation. 14 Features suggesting increased COVID-19 probability include de novo viral syndrome symptoms, inadequate social distancing, lack of typical heart failure features (weight gain or prior heart failure exacerbations), or lack of improvement with diuretics. Results can then be used to guide further assessment and intervention, and should in-person assessment be required, will inform the best setting for such an assessment (Figure-3 ).

An important question is continuation of neurohormonal blockade. Therapies under investigation to mitigate COVID-19 complications include immune modulating medications such as chloroquine and hydroxychloroquine. While these medications have myocardial toxicities, (eg. cardiomyopathy or worsening heart failure) this often takes months to develop, and short therapy duration may confer lower risk. 15, 16 Of concern, is the inhibitory effect of chloroquine on CYP2D6. Because CYP2D6 inhibition increases beta-blocker concentrations, it may cause greater decreases in blood pressure and heart rate. 17 Decisions to continue beta-blockade should consider respiratory and hemodynamic status; we recommend continuation of these agents in chronic systolic heart failure with a decreased dose if receiving an anti-malarial drug.

Of interest is the complex, incompletely understood, interaction of RAAS inhibition with SARS-CoV2, since the angiotensin-converting enzyme 2 (ACE2) receptor is used for host cell entry. Theoretically, ACE inhibitors (ACEI) and angiotensin receptor blockers (ARBs) may upregulate ACE2 and increase SARS-CoV2 susceptibility. 17, 18 This, however, experimental data suggest that ACEI may protect against lung injury and data from the SARS-CoV 2002-2003 epidemic where ARBs were proposed as potential 11 SARS therapeutics. 19, 20 Given incomplete/conflicting data, the its been recommended to continue RAAS inhibition in COVID-19. A multicenter retrospective study (>1000 hypertension patients) with COVID-19 suggested improved survival with an ACEI or ARB. 21 We continue these medications in patients with hypertension, chronic systolic heart failure in the absence of shock or renal disease.

Most important in management of heart failure patients with COVID-19 is maintained euvolemia and rapidly correct underlying hypoxemia to prevent more severe complications. In this context, cardiology consultation can assist the non-ICU COVID-19 patient.

Drug-induced QT interval prolongation and torsades de pointes Chloroquine, hydroxychloroquine with or without azithromycin and other antiviral medications are purported to benefit COVID-19 patients. These medications are relatively weak inhibitors of cardiac potassium channels (mainly I kr ) responsible for repolarization; when used alone in healthy patients result in only minor QT-prolongation.

Chloroquine has been used for malaria prophylaxis worldwide and drug-induced torsades de pointes and life-threatening ventricular tachyarrhythmias are rare in these patients, even with prolonged use. 22,23 In contrast, anticipated duration of exposure to these medications for COVID-19 is relatively short, 5-10 days. However, when two or more QT-interval prolonging drugs are used together, or used in older critically ill patients with multiple risk factors for arrhythmias related to QTprolongation (see below), prolongation of repolarization may be sufficient to result in life-threatening proarrhythmia, polymorphic ventricular tachycardia/torsades de pointes. 24 Although only a small proportion of patients with QT-prolongation develop torsades, it is most likely to occur when the QTc is ≥500 msec. The half-life of hydroxychloroquine is 40-60 days 25 , raising the possibility that drug-induced QTc prolongation could remain for a substantially longer period than actual drug administration, and if a QT-prolonging drug were added, risk of torsades may increase. QT-prolongation may not be the only cause of ventricular arrhythmias in COVID-19 patients receiving hydroxychloroquine or other antivirals; viral myocarditis, and/or other organ damage altering drug metabolism may increase arrhythmia susceptibility.

Preliminary data indicate that most COVID-19 patients showed minor increases in QTc duration on combination hydroxychloroquine and azithromycin, yet 12% had QTc prolongation >60 milliseconds from baseline and 11% developed QTc intervals >500 milliseconds. 26 Another study found QTc prolongation >500 msec in 19% of patients given higher doses of chloroquine. 27 Most of these patients were also receiving oseltamivir, which also may prolong the QTc. ICU patients with COVID-19 pneumonia may be particularly prone to excessive QT-prolongation, especially when hydroxychloroquine is combined with azithromycin. 28, 29 Prior to COVID-19, a risk score for predicting QT-prolongation in ICU patients was developed. 30 Risk factors receiving: 1-point included age ≥68 years, female sex and loop diuretic; 2-points serum potassium ≤3.5, admission QTc ≥450 msec, acute myocardial infarction; 3-points one QTc-prolonging drug, two or more QTc-prolonging drugs, sepsis, and heart failure. The maximum risk score was 21. Patients at low risk for QT prolongation/torsades de pointes were defined as those with a score ≤6 points, 13 moderate risk 7-10 points, and high risk ≥11 points. Importantly, loop diuretic, low potassium, concomitant QT-prolonging drugs are modifiable. This scoring system was incorporated into an algorithm by others 31 (Figure-4) . A baseline QTc is obtained using 12-lead ECG. If the QRS is wide (bundle branch block or ventricular pacing), a correction can be estimated by the following formula:

Wide-QRS-adjusted QTc = QTc -(QRS -100), all in milliseconds.

Utilizing the baseline QTc and risk score 30 31 Single-lead telemetry or smart-phone tracings are not sufficiently accurate for QTc monitoring, but many telemetry systems have the ability to obtain multiple simultaneous leads, and the longest QT-interval measured from those leads is a reasonable estimate of the QTc. The FDA has approved smart-phone applications providing simultaneous 6-lead ECGs for QTc monitoring. The smart-phone can either be a placed in a sterile bag and the recording apparatus sanitized after every use, or the patient can use their own smart-phone. 31, 33, 34 Arrhythmia Management in COVID-19

In patients with COVID-19, cardiovascular complications may be associated with serious arrhythmias: arrhythmias occurred in 17% of hospitalized patients and 44% of those admitted to the ICU, but details were lacking. 35 COVID-19 is associated with myocarditis and myocardial ischemia; both may lead to ventricular tachyarrhythmias, atrial tachyarrhythmias, or bradycardia/atrioventricular conduction block. Associated hypoxia, shock, and electrolyte disturbances also contribute to arrhythmias. Arrhythmia management is per usual arrhythmia guidelines. Bradyarrhythmias may be transient and, if pacing is required, one can consider temporary rather than permanent pacing. Special considerations may apply in patients with pre-existing arrhythmias, especially in those already receiving antiarrhythmic drugs that prolong the QT-interval (sotalol and dofetilide). Doses may need to be adjusted or discontinued if hydroxychloroquine or other QT-prolonging COVID-19 therapies are employed.

Amiodarone also prolongs the QT-interval but usually does not cause torsades de pointes. Patients with pre-existing long QT-syndromes should be given QT-prolonging drugs only after considering risk versus benefit and with very close QT-monitoring. High body temperture commonly unmasks serious ventricular arrhythmias in patients with Brugada syndrome. 36 Cardiac implantable electronic devices (CIED)

Remote CIED interrogations and device management via tele-monitoring should be performed. 37, 38 We recommend initiation of remote monitoring at device implantation;

patients not enrolled should be strongly encouraged to do so. Patients should transmit a device interrogation the day before a scheduled telemedicine visit, so the physician can review and discuss device function with the patient at the visit. Postoperative wound checks can be performed using video telemedicine. Office personnel should closely monitor CIED remote transmissions for significant arrhythmias or device malfunctions requiring early intervention.

Despite COVID-19, situations to consider in-person device interrogation 37, 38 include abnormalities on remote monitoring that may require device reprogramming, defibrillator shocks, presyncope/syncope symptoms concerning for arrhythmia that may require reprogramming, symptoms or monitor evidence of device/lead malfunction, suspected device infection, incessant arrhythmias (especially with multiple shocks), or need for emergent/urgent MRI. In a pacemaker-dependent patient undergoing surgery, a doughnut magnet can be placed over the pacemaker to ensure pacing during 16 electrocautery. During surgery in a patient with an implantable defibrillator, a magnet can be placed over the pulse-generator to suspend tachyarrhythmia detection and shocks.

The scale and speed of the COVID-19 pandemic is unprecedented; data change rapidly as this disease outpaces usual information-sharing and consensus processes. We are a collaborative team of physicians, respiratory therapists, pharmacists and nurses from multiple disciplines. While emphasis is on the lung, many important cardiovascular implications are emerging. Making these recommendations available to internists and hospitalists should help everyone to receive the best care possible. 

The variety of cardiovascular presentations of COVID-19. Circulation

Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China

Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection

Fourth universal definition of myocardial infarction

Cardiovascular implications of fatal outcomes of patients with Coronavirus Disease 2019 (COVID-19)

ISTH interim guidance on recognition and management of coagulopathy in COVID-19

Practical guidance for the prevention of thrombosis and management of coagulopathy and disseminated intravascular coagulation of patients infected with COVID-19

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical characteristics of Covid-19 in New York City

ST-segment elevation in patients with Covid-19 -A case series

Reduction in ST-segment elevation cardiac catheterization laboratory activations in the United States during COVID-19 pandemic

Management of acute myocardial infarction during the COVID-19 pandemic

ST-segment elevation, myocardial injury, and suspected or confirmed COVID-19 patients: Diagnostic and treatment uncertainties

Canadian Cardiovascular Society COVID-19 Rapid Response Team. Is it COVID-19 or is it heart failure? Management of ambulatory heart failure patients

Drugs that may cause or exacerbate heart failure: A Scientific Statement from the

Chloroquine cardiomyopathy -a review of the literature

Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic

COVID-19 and the cardiovascular system

Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics

Angiotensin-converting enzyme 2 protects from severe acute lung failure

Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality 20

Malaria Policy Advisory Committee, World Health Organization. The cardiotoxicity of antimalarials

The arrhythmogenic cardiotoxicity of the quinoline and structurally related antimalarial drugs: a systematic review

Considerations for drug interactions on QTc in exploratory COVID-19 (Coronavirus Disease 2019) treatment. Circulation

Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology

The QT interval in patients with SARS-CoV-2 infection treated with hydroxychloroquine/azithromycin

Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection: A 21 randomized clinical trial

Assessment of QT intervals in a case series of patients with Coronavirus Disease 2019 (COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit

Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for Coronavirus Disease

Development and validation of a risk score to predict QT interval prolongation in hospitalized patients

FDA Drug Safety Communication. FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems

Inpatient use of ambulatory telemetry monitors for COVID-19 patients treated with hydroxychloroquine and/or azithromycin

Clinical characteristics of 138 hospitalized patients with 2019 Novel Coronavirus-infected pneumonia in Wuhan

SARS-CoV-2, COVID-19 and inherited arrhythmia syndromes. Heart Rhythm

Cardiac Implantable Electronic Device (CIED) Management

Guidance for cardiac electrophysiology during the coronavirus (COVID-19) pandemic from the Heart Rhythm Society COVID-19 Task Force

American College of Cardiology; and the Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology